Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry - Nature reviews Clinical oncology, 2019 - nature.com
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
Clinical lessons learned from the first leg of the CAR T cell journey
RG Majzner, CL Mackall - Nature medicine, 2019 - nature.com
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
Tumor antigen escape from CAR T-cell therapy
RG Majzner, CL Mackall - Cancer discovery, 2018 - AACR
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
[HTML][HTML] The principles of engineering immune cells to treat cancer
Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can
serve as a powerful new class of cancer therapeutics. Clinical experience has helped to …
serve as a powerful new class of cancer therapeutics. Clinical experience has helped to …
A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
M Boulch, M Cazaux, Y Loe-Mie, R Thibaut… - Science …, 2021 - science.org
Chimeric antigen receptor (CAR) T cell therapy relies on the activity of a large pool of tumor-
targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions …
targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions …
Programming CAR-T cells to kill cancer
T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …
antigens have led to high complete response rates in patients with haematologic …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
New development in CAR-T cell therapy
Z Wang, Z Wu, Y Liu, W Han - Journal of hematology & oncology, 2017 - Springer
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …
Genetically engineered T cells for cancer immunotherapy
D Li, X Li, WL Zhou, Y Huang, X Liang… - … and Targeted Therapy, 2019 - nature.com
T cells in the immune system protect the human body from infection by pathogens and clear
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …